Works matching DE "HEPATOTOXICOLOGY -- Risk factors"

Results: 181
    1

    Drug-induced liver injury related to avacopan therapy.

    Published in:
    Rheumatology, 2025, v. 64, n. 5, p. 2533, doi. 10.1093/rheumatology/keae689
    By:
    • Mori, Kentaro;
    • Shirai, Tsuyoshi;
    • Mutoh, Tomoyuki;
    • Inoue, Jun;
    • Fujishima, Fumiyoshi;
    • Kubo, Satsuki;
    • Watanabe, Hirofumi;
    • Sato, Satoko;
    • Narita, Mamoru;
    • Hoshi, Yosuke;
    • Sato, Hiroko;
    • Fujii, Hiroshi
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT).

    Published in:
    European Journal of Clinical Pharmacology, 2013, v. 69, n. 3, p. 605, doi. 10.1007/s00228-012-1357-8
    By:
    • Gulmez, Sinem;
    • Larrey, Dominique;
    • Pageaux, Georges-Philippe;
    • Lignot-Maleyran, Séverine;
    • Vries, Corinne;
    • Sturkenboom, Miriam;
    • Perez-Gutthann, Susana;
    • Bénichou, Jacques;
    • Bissoli, Franco;
    • Horsmans, Yves;
    • Bernuau, Jacques;
    • Stricker, Bruno;
    • Thorburn, Douglas;
    • Blin, Patrick;
    • Moore, Nicholas
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Drug-Induced Liver Injury.

    Published in:
    Archives of Pathology & Laboratory Medicine, 2015, v. 139, n. 7, p. 876, doi. 10.5858/arpa.2014-0214-RA
    By:
    • Fisher, Kurt;
    • Vuppalanchi, Raj;
    • Saxena, Romil
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest

    Published in:
    HIV Medicine, 2012, v. 13, n. 7, p. 427, doi. 10.1111/j.1468-1293.2012.00994.x
    By:
    • Girard, P-M;
    • Campbell, TB;
    • Grinsztejn, B;
    • Hartikainen, J;
    • Rachline, A;
    • Nijs, S;
    • Witek, J
    Publication type:
    Article
    46
    47
    48
    49
    50

    Levoketoconazole.

    Published in:
    American Journal of Health-System Pharmacy, 2022, v. 79, n. 8, p. 607, doi. 10.1093/ajhp/zxac018
    Publication type:
    Article